The class of molecules behind one of biotech's biggest Alzheimer's failures gets a new lease on life
Denovo Biopharma has spent the last decade trying to resurrect drugs that failed at other companies, but it had never waded into a class of molecules that failed quite as spectacularly as 5HT6 serotonin, an oft-failed shot on goal in Alzheimer’s. But, in the wake of Biogen’s derided success with aducanumab, all options appear back on the table.
On Thursday, the San Diego-Chinese biotech announced it’s licensed the once-abandoned Alzheimer’s drug idalopirdine from Lundbeck for an undisclosed fee.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.